Actavia Life Sciences Inc Revenue Growth Rates (RASP), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Actavia Life Sciences Inc   (RASP)
 

RASP's Revenue Growth by Quarter and Year

Actavia Life Sciences Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

RASP Revenue (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
4th Quarter September -
3rd Quarter June -
2nd Quarter March 0.00
1st Quarter December 0.00
FY 0.00





RASP Revenue second quarter 2024 Y/Y Growth Comment
Actavia Life Sciences Inc in the second quarter 2024 recorded of $ 0.00 millions.

Looking into second quarter 2024 results within Major Pharmaceutical Preparations industry 140 other companies have achieved higher Revenue growth. While Actavia Life Sciences Inc ' s Revenue meltdown of -100% ranks overall at the positon no. 2362 in the second quarter 2024.


RASP Revenue ( Y/Y Growth %) 2024
 2023 2022 2021
4th Quarter September - - - -
3rd Quarter June - - - -
2nd Quarter March - 0 % - -
1st Quarter December - - - -
FY   - -93.33 % - -

Financial Statements
Actavia Life Sciences Inc 's second quarter 2024 Revenue $ 0.00 millions RASP's Income Statement
Actavia Life Sciences Inc 's second quarter 2023 Revenue $ 0.01 millions Quarterly RASP's Income Statement


RASP Revenue (Quarter on Quarter Growth %)

 2024
 2023 2022 2021
4th Quarter September - - -42.86 % -
3rd Quarter June - - 600 % -
2nd Quarter March - - -66.67 % -
1st Quarter December - - - -
FY (Year on Year)   - -93.33 % - -


Back to RASP Growth rate Comparisons >> Back to RASP Growth rate Comparisons >>


Revenue second quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #141
Healthcare Sector #382
Overall #2362

Revenue Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Revenue second quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #141
Healthcare Sector #382
Overall #2362
Revenue Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Revenue by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Actavia Life Sciences Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


RASP's II. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


RASP's II. Quarter Q/Q Revenue Comment


Actavia Life Sciences Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2024)		 12 Months Ending
(Dec 31 2023)		 12 Months Ending
(Sep 30 2023)		 12 Months Ending
(Jun 30 2023)		 12 Months Ending
(Mar 31 2023)
Cumulative Revenue 12 Months Ending $ 0.00 $ 0.00 $ 0.00 $ 0.00 $ 0.12
Y / Y Revenue Growth (TTM) - - - - -
Year on Year Revenue Growth Overall Ranking # # # # #
Seqeuential Revenue Change (TTM) - - - - -1.79 %
Seq. Revenue Growth (TTM) Overall Ranking # 2362 # 0 # 0 # 0 # 0


Cumulative Revenue growth Comment
Actavia Life Sciences Inc realized trailing twelve months of $ 0 millions, in the Mar 31 2024, compare to Revenue of $ 0 millions a year ago.

Actavia Life Sciences Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
 0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 141
Sector # 382
S&P 500 # 2362
Cumulative Revenue growth Comment
Actavia Life Sciences Inc realized trailing twelve months of $ 0 millions, in the Mar 31 2024, compare to Revenue of $ 0 millions a year ago.

Actavia Life Sciences Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 141
Sector # 382
S&P 500 # 2362




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
RASP's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue meltdown for the quarter ending Mar 31 2024 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2024
Collegium Pharmaceutical Inc -0.21%$ -0.215 millions
Mettler toledo International Inc -0.30%$ -0.300 millions
Icu Medical Inc-0.42%$ -0.423 millions
Lifeloc Technologies Inc -0.51%$ -0.513 millions
Regeneron Pharmaceuticals Inc -0.54%$ -0.541 millions
Envista Holdings Corporation-0.62%$ -0.622 millions
3m Company-0.64%$ -0.644 millions
Orgenesis Inc -0.70%$ -0.704 millions
T2 Biosystems Inc -0.82%$ -0.818 millions
Vyne Therapeutics Inc -1.01%$ -1.010 millions
Enhabit Inc -1.02%$ -1.018 millions
Valneva Se-1.11%$ -1.112 millions
Ge Healthcare Technologies Inc -1.50%$ -1.502 millions
Baxter International Inc -1.56%$ -1.562 millions
Y mabs Therapeutics inc -1.58%$ -1.580 millions
Pacific Biosciences Of California Inc -1.59%$ -1.589 millions
Cartesian Therapeutics Inc -1.65%$ -1.650 millions
Viatris Inc -1.76%$ -1.762 millions
Zimvie Inc -1.84%$ -1.836 millions
Sight Sciences Inc -1.87%$ -1.870 millions
Opus Genetics Inc -2.17%$ -2.173 millions
Vaso Corporation-2.51%$ -2.513 millions
Dentsply Sirona Inc -2.56%$ -2.556 millions
Alpha Pro Tech Ltd -2.78%$ -2.775 millions
Prestige Consumer Healthcare Inc -2.82%$ -2.817 millions
West Pharmaceutical Services Inc -2.99%$ -2.986 millions
Wave Life Sciences Ltd -3.02%$ -3.024 millions
Fulgent Genetics Inc -3.12%$ -3.119 millions
Integra Lifesciences Holdings Corp-3.14%$ -3.144 millions
Accelerate Diagnostics Inc -3.17%$ -3.165 millions


About Actavia Life Sciences Inc Revenue Growth Rates (RASP), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Actavia Life Sciences Inc (CIK 1582249).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001213900-24-045020
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Actavia Life Sciences Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.